An official website of the United States government

Publication Information

PubMed ID
Public Release Type
Journal
Publication Year
2019
Authors
Hayek Salim S., Landsittel Douglas P., Wei Changli, Zeier Martin, Yu Alan S.L., Torres Vicente E., Roth Sharin, Pao Christina S., Reiser Jochen
Studies

Abstract

Soluble urokinase plasminogen activator receptor (suPAR), a marker of inflammation, is also an independent marker for incidence and progression of renal diseases. Mechanistically, it has been shown to activate podocytes in glomerular diseases. In this study, the authors provide the first description linking suPAR levels with disease progression for a major genetic renal disease that mainly affects the extraglomerular compartment, autosomal dominant polycystic kidney disease (ADPKD). They found an association between suPAR levels and height-adjusted total kidney volume, independent of age, sex, race, hypertension, and eGFR. In addition, patients with suPAR levels >2.82 ng/ml had a 3.38-fold increase in risk of incident ESRD. These findings suggest that suPAR levels may be useful for early identification of patients with ADPKD at high risk of disease progression.